Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vactosertib by MedPacto for Osteosarcoma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...
Vactosertib by MedPacto for Refractory Multiple Myeloma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase...
Vactosertib by MedPacto for Relapsed Multiple Myeloma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase...
Vactosertib by MedPacto for Gastric Cancer: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Vactosertib by MedPacto for Hepatocellular Carcinoma: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...
Vactosertib by MedPacto for Benign Tumor: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase II for Benign Tumor. According to GlobalData, Phase II...
Vactosertib by MedPacto for Solid Tumor: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Vactosertib by MedPacto for Colorectal Cancer: Likelihood of Approval
Vactosertib is under clinical development by MedPacto and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...